Andere Sprachen Liquidia Corporation

Aktien

A2JRNS

US53635D2027

LQDA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
13.29 ^USD	-3.77%		-4.73%	+10.47%

01.04.	Liquidia sagt, dass die US FDA Yutrepia zur Behandlung von Bluthochdruck genehmigt hat	MT
20.03.	Liquidia Insider verkaufte Aktien im Wert von $452.183, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference	02.04.
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference	02.04.
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	01.04.
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	01.04.
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder	01.04.
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing	20.03.
Liquidia Corporation(NasdaqCM:LQDA) added to S&P Pharmaceuticals Select Industry Index	18.03.
Liquidia's 2023 Net Loss Widens, Revenue Increases -- Shares Advance Pre-Bell	13.03.
Liquidia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	13.03.
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update	13.03.
Certain Stock Units of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	12.03.
Certain Warrants of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	12.03.
Certain Options of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	12.03.
Certain Common Stock of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024.	12.03.
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024	06.03.
United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia	21.02.
Spotlight On Upcoming Oral Arguments – February 2024	13.02.
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress	30.01.
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA inhalation powder	26.01.
US FDA Yutrepia Review Delay 'Yet Another Setback' For Liquidia, Wedbush Says	25.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Liquidia Corporation

Aktien

A2JRNS

US53635D2027

LQDA

Andere Sprachen

Filter